The Role of mTOR Inhibitors in Feline Cardiac Remodeling

mTOR Inhibition and Feline Cardiac Health

The mechanistic target of rapamycin (mTOR) is a nutrient-sensing kinase that regulates cellular growth, proliferation, and protein synthesis. In cardiac tissue, chronic hyperactivation of the mTOR pathway is a primary driver of ventricular hypertrophy.

Breaking the Remodeling Cycle

By administering Sirofel™, the active Sirolimus molecule binds to the intracellular receptor FKBP12. This complex inhibits mTOR Complex 1 (mTORC1) activity. Consequently, the signals promoting pathological protein synthesis in cardiomyocytes are down-regulated, effectively slowing down or reversing the thickening of the ventricular wall.

Proactive Veterinary Intervention

The key to successful mTOR inhibition therapy is starting during the subclinical B1 or B2 stages. Delaying therapy until the heart has progressed to end-stage congestive failure limits the remodeling benefit, making early detection and weekly tablet protocols critical.